drugset / Trial / NCT04788745
Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Completed
21 enrolled
The University of Queensland
FightMND · collabJulius Clinical · collabKing's College London · collabUMC Utrecht · collab
NaSingle-groupOpen-labelTreatment
Summary
MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).
Timeline
- Start
- 2021-06-29
- Primary completion
- 2023-05-24
- Completion
- 2023-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trimetazidine | Small molecule | 35 mg | Oral |